Is a review published in Chemistry – A European Journal, August 2019
DOI 10.1002/chem.201903232
Pubmed ID 31429510
Authors
Oleksandr O Grygorenko, Dmitriy M. Volochnyuk, Sergey V. Ryabukhin, Duncan B. Judd

The CEO with be attending the SCI’s Fine Chemical Group one-day meeting to showcase cutting edge synthetic organic chemistry. The aim of the meeting is to highlight new synthetic approaches, disconnections and methods, and their application as developed by key researchers from both academia and industry. An exciting line up of leading academic and industrial scientists will present a series of lectures covering areas such as electrochemistry, C-H activation and new catalytic methods.

The CEO of Awridian Ltd attended the conference which was held at the Felder Centre Hatfield on 2nd May 2019

Ultra-large library docking for discovering new chemotypes

Nature volume 566, pages224–229 (2019) | Download Citation

If you are in the Boston Area in May and interested in the topic then this is the conference for you.

https://www.eventbrite.com/e/better-leads-better-drugs-innovation-in-screening-libraries-tickets-49774247113

Take a look at a Big-Pharma approach toward the enhancement of their screening library: The Next Generation Library Initiative (NGLI) at Bayer — against all odds? at
https://doi.org/10.1016/j.drudis.2018.12.003

It describes how Bayer’s HTS collection was increased by 500 000 newly designed compounds within 5 years and how this collaborative project, which involved all internal medicinal chemists using a crowd-sourcing approach, along with selected external partners, reached this ambitious goal.

2018 FDA drug approvals

The FDA approved a record 59 drugs last year (2018), but the commercial potential of these drugs is lacklustre.

Take a look at Asher Mullard’s article

Awridian is pleased to announce the opening of it’s new web site. Please take a look around: comments welcome.

The event which brings together stakeholders in pharmaceutical R&D outsourcing to share experience, develop knowledge and skills and build new and existing business partnerships. The scope of the event for 2019 will cover Discovery Outsourcing and Development Stage CMC Outsourcing for both Small Molecules and Biologics.

We look forward to building on a highly successful event in 2018 where delegate numbers increased by over 30% and average ratings reached 8 out of 10 (up from 7.68 in 2017). We look forward to developing the event further in 2019 to meet all your Discovery and CMC outsourcing needs. Go to https://www.bio2bevents.com/forthcoming-events/bos2019 L